Health & Fitness
Health and Fitness
Health and Fitness
Thu, February 19, 2009
Wed, February 18, 2009 ReGen Biologics Initiates Training Program for U.S. Surgeons
HACKENSACK, N.J.--([ BUSINESS WIRE ])--ReGen Biologics (OTC: RGBO) ("ReGen") reported the first surgeon training course in support of U.S. launch for the Menaflex™ collagen meniscus implant. The focus of the course was to "train the trainers" who will be instrumental in educating U.S. surgeons interested in the Company's recently cleared device.
The four U.S. surgeons – Dr. Charles Beck of West Jordan, Utah, Dr. Heinz Hoenecke and Dr. James Tasto of San Diego, and Dr. William Montgomery of San Francisco - traveled to Innsbruck, Austria to meet with European surgeons who have been actively implanting the Menaflex device. The course format allowed participants to share cases, review clinical data, and discuss specifics related to patient selection, surgical technique, and rehabilitation protocol. The course was coordinated through The Orthopedic Academy, an international network of sports medicine surgeons.
"This is an important step in establishing our U.S. surgeon training program," said Gerald E. Bisbee, Jr., Ph.D., Chairman and CEO. "The experience gained by surgeons in Europe has proven to be extremely beneficial to our understanding of how to most efficiently share clinical data and technical methods with new surgeons," Dr. Bisbee continued.
Following the Innsbruck meeting, the U.S. attendees are preparing to support training meetings to take place across the U.S., after the official product introduction which is scheduled for February's American Academy of Orthopaedic Surgeons meeting in Las Vegas, Nevada.
About The Orthopedic Academy:
The Orthopedic Academy is an international learning network of sports medicine surgeons dedicated to training each other, learning about new, cutting edge procedures and techniques, and pursuing evidence-based surgery. The Orthopedic Academy provides opportunities for top tier sports medicine surgeons to participate in collaborative research and review and develop new devices and techniques. For more information visit [ www.orthopedicacademy.org ].
About ReGen Biologics, Inc.:
ReGen Biologics is an orthopedic products company that develops, manufactures and markets innovative tissue growth and repair products for U.S. and global markets. ReGen's first approved product using its proprietary biological collagen scaffold technology is the Menaflex™ collagen meniscus implant, which is cleared for sale in Europe and other countries and marketed through ReGen's European subsidiary, ReGen Biologics AG. ReGen received FDA clearance in the U.S. for the Menaflex device in December 2008. Visit [ www.regenbio.com ] and [ www.menaflex.com ] for more information.
